Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026. The presentation is scheduled for March 10, 2026 at 2:20 p.m. ET with CEO Chris Giordano, CMO Stuart Rich, and CBO Douglas Randall.
A live and archived webcast will be available on the company’s investor relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction – TENX
In the Mar 3 session, TENX declined 1.72%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Investor conference | Neutral | +1.4% | Announcement of Guggenheim biotech summit fireside chat with senior management. |
| Dec 17 | Phase 3 update | Positive | +5.7% | Phase 3 LEVEL powering update and initiation of global LEVEL-2 trial plans. |
| Nov 25 | Investor conferences | Neutral | +4.4% | Participation in two December healthcare investor conferences via fireside chats. |
| Nov 12 | Earnings and update | Neutral | -4.3% | Q3 2025 financial results with clinical timelines and patent/cash runway details. |
| Nov 06 | KOL call | Neutral | -2.4% | Announcement of virtual KOL call discussing TNX-103 Phase 3 program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and corporate update communications have often coincided with modest price moves, generally aligning with the neutral-to-positive tone of announcements.
Over the last several months, Tenax has regularly engaged investors through conferences and KOL events, while advancing Phase 3 programs and reporting quarterly results. Prior updates highlighted strong powering for the Phase 3 LEVEL trial, launch plans for LEVEL-2, and a cash runway extending through 2027. Investor conference participation in late 2025 and early 2026 has been frequent. Today’s Leerink conference fireside chat continues this pattern of outreach rather than marking a new clinical or financial inflection.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL.
Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer; Stuart Rich, M.D., Chief Medical Officer; Douglas Randall, Chief Business Officer
Date and Time: March 10, 2026, at 2:20 p.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
